Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
5.19
-0.03 (-0.57%)
Mar 6, 2026, 10:17 AM EST - Market open
Company Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease.
The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Carole Ben-Maimon |
Contact Details
Address: Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 United States | |
| Phone | 844 511 9056 |
| Website | larimartx.com |
Stock Details
| Ticker Symbol | LRMR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374690 |
| CUSIP Number | 517125100 |
| ISIN Number | US5171251003 |
| Employer ID | 20-3857670 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | Chief Executive Officer, President and Director |
| Michael Celano CPA | Secretary and Chief Financial Officer |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer |
| John Berman | Vice President of Finance and Administration |
| Jennifer Spokes Johansson | Vice President of Legal and Compliance |
| Dr. Russell G. Clayton Sr., D.O. | Chief Medical Officer |
| Francis Michael Conway CPA | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | SCHEDULE 13D/A | Filing |
| Feb 27, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 424B5 | Filing |
| Feb 25, 2026 | 424B5 | Filing |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Jan 22, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 17, 2025 | 8-K | Current Report |